Volume 22, Number 10—October 2016
Dispatch
Viral RNA in Blood as Indicator of Severe Outcome in Middle East Respiratory Syndrome Coronavirus Infection
Table 2
Characteristic |
Respiratory specimen type |
Blood specimen type | |
---|---|---|---|
EDTA whole blood |
Serum |
||
No. specimens |
20 sputum; 1 endotracheal aspirate |
21 |
21 |
Days from initial confirmatory diagnosis using respiratory specimens to blood sampling |
Set as day 0 |
1.4 (median 1,
range 0–5) |
1.5 (median 1,
range 0–5) |
Viral gene region rRT-PCR | |||
Upstream of E | |||
Total positive results/total tests (%) | 21/21 (100) | 6/21 (29) | 6/21 (29) |
Median Ct (range) | 28.48 (19.70–33.46)† | 37.55 (35.34–38.07) | 36.88 (34.24–38.14) |
Open reading frame 1a | |||
Total positive results/total tests (%) | 21/21 (100) | 0/21 (0) | 0/21 (0) |
Median Ct (range) | 29.28 (21.00–34.21)† | Not detected | Not detected |
Nucleocapsid | |||
Total positive results/total tests (%) | Not performed | 7/21 (33) | 7/21 (33) |
Median Ct (range) | Not performed | 36.37 (35.62–38.04) | 34.62 (32.93–38.84) |
*Ct, cycle threshold; rRT-PCR, real-time reverse transcription PCR.
†One patient whose Ct was not reported was excluded.
Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.